|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 48/00 | (2006.01) |
| A61K 35/761 | (2015.01) | ||
| A61P 27/02 | (2006.01) | ||
| C12N 15/09 | (2006.01) |
| (11) | Number of the document | 3795181 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20196657.9 |
| Date of filing the European patent application | 2017-06-16 | |
| (97) | Date of publication of the European application | 2021-03-24 |
| (45) | Date of publication and mention of the grant of the patent | 2025-08-06 |
| (46) | Date of publication of the claims translation | 2025-12-29 |
| (30) | Number | Date | Country code |
| 201662351234 P | 2016-06-16 | US |
| (72) |
BLUMENKRANZ, Mark , US
GASMI, Mehdi , US
|
| (73) |
Adverum Biotechnologies, Inc. ,
100 Cardinal Way, Redwood City, CA 94063,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | AMD gydymas naudojant AAV2 variantą su afliberceptu |
| TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT |